Immunovaccine Announces 2011 Second Quarter Results
(firmenpresse) - HALIFAX, NOVA SCOTIA -- (Marketwire) -- 08/24/11 -- Immunovaccine Inc. (TSX VENTURE: IMV), a clinical stage vaccine development company, released today its financial and operational results for the second quarter ended June 30, 2011 ("Q2 2011"). The Company's unaudited condensed interim consolidated financial statements for Q2 2011, filed in accordance with International Financial Reporting Standards ("IFRS"), and the management discussion and analysis (MD&A), are available at .
"During this quarter, we received Phase I results indicating our first DepoVax™-based therapeutic cancer vaccine, DPX-0907, is well tolerated and can induce a vaccine specific immune response," said Dr. Marc Mansour, Chief Operating Officer and Chief Science Officer of Immunovaccine Inc. "We leveraged these results to support a Phase I/II investigational new drug application for DPX-Survivac and announced that it was cleared by the FDA on June 20, 2011. We anticipate initiating the Phase I clinical trial for DPX-Survivac in the fourth quarter of this year."
Highlights:
DPX-Survivac
DPX-0907
Corporate
Financial Results
As a result of decreased revenue and increased expenses in research and development (R&D) relating to DPX-Survivac pre-clinical research and manufacturing the clinical batch of DPX-Survivac, the Company's net loss increased from $1,638,000 during the three month period ended June 30, 2010 to a loss of $2,044,000 in Q2 2011. These increases were offset by a $235,000 decrease in expenses associated with the Phase I clinical trial of DPX-0907, a $170,000 decrease in business development (BD) costs, and a decrease in general and administration (G&A) expenses of $189,000.
For Q2 2011, the Company reported total R&D expenses of $1,488,000 (less investment tax credits of $36,000 and government assistance of $34,000), total BD expenses of $194,000, and total G&A expenses of $404,000, compared to total R&D expenses of $1,065,000 (less investment tax credits of $33,000 and government assistance of $365,000), total BD expenses of $364,000 and total G&A expenses of $593,000 for the three months ended June 30, 2010.
At June 30, 2011, the Company had cash resources of $7.5 million and identified additional potential cash resources of $3.7 million. The Company's "cash burn rate" (defined as net loss for the period adjusted for non-cash transactions) was approximately $1.8 million for Q2 2011. Management is of the belief that the Company has sufficient funds to execute its existing strategy, including advancing the Phase I clinical trial of DPX-Survivac, and has adequate working capital until the third quarter of 2012.
As at August 24, 2011, the number of issued and outstanding common shares is 53,987,084 with 3,440,650 stock options outstanding. The number of outstanding warrants on June 30, 2011 is 4,137,556.
Outlook
Immunovaccine continues to advance its business strategy into 2011, maximizing the broad potential of DepoVax™ vaccine delivery platform. The Company is focusing on advancing the vaccine candidates that show the most compelling technical results combined with identified commercial opportunities.
Achieving positive Phase I clinical results for DPX-0907 has generated important safety and immunogenicity data that will aid in the rational design of future DPX-0907 cancer vaccine trials and support the future use of DepoVax for delivering multi-peptide based vaccines. These clinical trial results also helped Immunovaccine receive FDA clearance, within the minimum review period, to take DPX-Survivac into human clinical trials.
The second half of 2011 will see the continued development of DPX-Survivac with the start of Phase I clinical trial in the U.S., as well as publishing the Phase I final results for the DPX-0907 therapeutic cancer vaccine.
Immunovaccine Inc. (TSX VENTURE: IMV) is a clinical stage vaccine development company focused on the commercialization of its patented DepoVax™ vaccine delivery technology and product candidates. The Company continues to strengthen its vaccine pipeline through licensing and strategic partnerships to develop therapeutic cancer and infectious disease vaccines. .
This press release contains forward-looking information under applicable securities law. All information that addresses activities or developments that we expect to occur in the future is forward-looking information. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. However, they should not be regarded as a representation that any of the plans will be achieved. Actual results may differ materially from those set forth in this press release due to risks affecting the Company, including access to capital, the successful completion of clinical trials and receipt of all regulatory approvals. Immunovaccine Inc. assumes no responsibility to update forward-looking statements in this press release.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contacts:
Immunovaccine Inc.
Kimberly Stephens
CFO
(902) 492-1819
Immunovaccine Inc.
Jennifer Ayotte
Director Communications
(902) 492-1819
Tiberend Strategic Advisors, Inc.
Andrew Mielach
(212) 827-0020
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 24.08.2011 - 06:15 Uhr
Sprache: Deutsch
News-ID 1033331
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
HALIFAX, NOVA SCOTIA
Phone:
Kategorie:
Surgery & Treatments
Anmerkungen:
Diese Pressemitteilung wurde bisher 198 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Immunovaccine Announces 2011 Second Quarter Results
"
steht unter der journalistisch-redaktionellen Verantwortung von
Immunovaccine Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
